NEW YORK (TheStreet) -- Chimerix (CMRX) - Get Report shares closed trading down 4.31% to $39.03 in trading on Friday after the pharmaceutical company reported its fourth quarter earnings results before the opening bell today.

The company reported a fourth quarter net loss of $20.2 million, or a loss of 52 cents per diluted share on an adjusted basis. The company also generated $1.2 million in revenue during the period, beating analysts $1.1 billion expectations for the period.

Analysts on average were expecting the company to report a net loss of 51 cents per diluted share.

For the year the company reported a net loss of $59.3 million, or $1.80 per share, on revenue of $4 million.

"...we plan to continue to develop additional compounds through our discovery platform, capitalizing on our experienced group of scientists, unique chemical library, and proprietary lipid conjugate technology," the company said of its plans for the current fiscal year.

TheStreet Ratings team rates CHIMERIX INC as a Hold with a ratings score of C-. TheStreet Ratings Team has this to say about their recommendation:

"We rate CHIMERIX INC (CMRX) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

• You can view the full analysis from the report here: CMRX Ratings Report

CMRX

data by

YCharts